About this trial
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Both male and female will be included
Negative pregnancy test and effective contraception.
Mild and moderate UC patients
Disqualifiers
Breast feeding
Significant liver and kidney function abnormalities
Diabetic patients
Colorectal cancer patients
Trial design
Treatments tested in this trial
- Mesalamine
- Pentoxifylline
Treatment groups
Sponsors and collaborators
Ihab Elsayed Hassan
Lead sponsor
Tanta University
Sponsor institution